Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
2011
2012
2013
19.2
34.2
28.4
18.2
12.5
13.5
24.1
25.2
17.5
18.5
21.2
12.52
Analytical interpretation
The latest orgims rankings of the market shares of pharma companies in the domestic market for
the 12 months ended may have thrown up many insights. in the cipla10.5%,19.2%,,12.5%,,17.5
%,in the year 2010 -2013 mankind 27.5%, ,34.5%,,13.5%,,18.5 %,sun pharma 15.5%,, 28.5%,
24.1%, ,21.2%, lupin 12.3%,, 18.2%, ,25.2%,, 12,52% in the year 2010 -2013.
COMPANY
LUPIN
MANKIND
PROFILE
GLAXOS
PFIZER
CIPLA
MITHKLINE
Established
1968
1995
1924
1849
1935
Turnover
1.39 billion
30 billion
26.4 billion
51.6 billion
1.5 billion
Employee
12710
10000
100000
103700
26000
Product Range
Anti-TB,
Antibiotics,
Anti-infective,
Pain
Cardiovascular,
Cephalosporin
Antifungals,
and
Gastrointestinal,
Anti-infective,
ogy, diabetes,
,Allergy and
oncology,
Respiratory ,
cardiovascular
Neuroscience
disease and
Antibacterial,
respiratory,
inflammatory
Dermal
respiratory
Stem Cells
urology,
and respiratory
and Erectile
diseases.vaccines, for
and
children health,
therapy.
Dysfunction
Cardiovascula NSAIDs,Anthel
r drugs,
mintic,
categories
FMCG
brands:
Unwante
d72,
PregaNe
oncology,
osteoporosis,
AIDS
caused by H,
OTC &
anti-malarial,
influenza,
chickenpox,
diphtheria, pertussis,
tetanus, rotavirus,
cervical cancer,
streptococcus
pneumonia and
Antibody
Technologies
,Allergy and
Respiratory,P
eptide
Technologies,
Tissue Repair
ws,
others.
Pain
Kustody,
,Genitourinary
Adiction,
,Allergy and
Gas-O-
Respiratory ,
Fast,
Molecular
and
and
Manforc
Translational
Medicine
Condoms
Reduction in support costs between SaaS SFA & onsite SFA solution
Bringing CRM and Branding together. Consistent product or service proposition at all
times
Year
2005-06
2006-07
2007-08
2008-09
2009-10
2010-11
2011-12
2012-13
2013-14
Revenues ( rs crore )
338
486
618
812
1043
1588
1909
2383
3000
Analytical interpretation
The above data the researcher analyze that the growth of mankind company in india
Making a strategic decision on what problems the CRM system is to address, what
improvements or changes it should bring in the business processes of the organization.
Empowering team members with the required authority to complete the tasks.
Selecting the correct implementation partner. They must have both vertical and horizontal
business knowledge, as well as technical expertise.
anal
Analytical interpretation
The above data the researcher analyze that the CRM policy of mankind company in india
Ensuring executive sponsorship and top management support. Empowering team members with
the required authority to complete the tasks. Selecting the correct implementation partner. They
must have both vertical and horizontal business knowledge, as well as technical expertise.
LUPIN
MANKIND
CHAIN
GLAXOS
PFIZER
CIPLA
MITHKLINE
COMPONE
NTS
FIRM
corporate office
corporate office
corporate office
biotechnology
Research Centre
INFRASTRU
CTURE
R&D center
Manufacturing
R& D department
Manufacturing
Manufacturing
Units
Units
R& D unit
R& D unit
HUMAN
Recruitment ,
RESOURCE training,
MANAGEM Employee benefit
ENT
Recruitment , training,
Compensation,
Talent
HR Generalist,
Organizational
Acquisition,
Talent
Development,
Learning and
Acquisition,
Learning and
Development
Development
Learning and
Development
AND
Advanced Drug
Neuroscience
Regenerative
API
(ADDS) Research,
resistance, and
Novel Drug
Epigenetic-turn-ons Medicine
Formulation
Discovery and
and turn-offs
development
Molecular and
Development
Translational
(NDDD),
Medicine
Biotechnology
,Antibody
Research.
Technologies ,Pe
device
ptide
Technologies,
Tissue Repair
Operation
manufacturing
operations are
, formulate, fill,
to set the
formulations
pack, control,
standard
sophisticated
and Japan.
Business
technologically
manufacturing
supplying
Operational
opmentand man
Sustainability
ufacture of
ons.
medicines
purpose
aggressive marketing
commercial
Strategy
Strategic tie
policy , customer
teams are
Marketing
engagement model
responsible for
Robust
understanding our
Distribution
SERVICES
Market Access
marketing with
global MNCs
Network
Employee self
Medical help,
nsumer
Purchase and
service
healthcare India
Dividend
Shareholder
Reinvestment
information
Customer help
Plan,
Direct Deposit of
Pfizer Dividends
Threat of New
entrants
Lupin
Low
Medium
Low
High
High
Pfizer
Low
Low
Low
High
High
GlaxoSmithKline
Low
Low
Low
High
High
Mankind
Medium
Low
Low
Mediu low
m
Cipla
Low
Low
Low
Mediu High
m
MANKIND PFIZER
CIPLA
1. Excellent
research and
development
WEAKNESS 1.High
1.very niche
dependence on category of
global
market
formulation 2. less
business
regular sell
1.issue of
1.Tough
safety of drugs competition
2. Mergers and
acquisitions
1.positive brand
image
2. Fixed-Dose
combination
3. anti-infective and
3. Strong brand anti-asthmatic
formulations
name
2. Patent
expiry
1.
Negat
2.Negative brand ive
camp
image
aigns
(healthcare
2.Forecasting
done on
technological
level is less
fraud)
2.
Toug
h
comp
etitio
n
3.It operates in
low growth
segments
OPPORTUN 1. Emerging
ITY
technological
trends in drug
delivery
2.
Increasing pre
valence of TB
by
AHF
1. Related
1. Increasing awareness
diversificatio 2. mergers and acquisitions
n
2. Growth in
modern retail
1.
Alzh
eime
rs
dise
ase
med
icati
on.
2.Inc
rease
d
inve
stme
nt in
the
budd
ing
mark
ets.
THREATS
1.Rigid
opposition
11
..
u
nC
so
un
cs
ct
ea
sn
st
f
up
lr
i
nc
ee
w
r
Pi
rs
oe
ds
u
c2
t.
s
2R
.u
p
R
ee
ge
u
ld
ae
tp
or
re
yc
i
ea
nt
vi
io
rn
o3
n.
m
eF
nl
tu
3c
.t
E
u
ca
ot
ni
oo
m
n
is
c
i
sn
l
oc
w
u
dr
or
w
e
nn
c
y
e
x
c
h
a
n
g
e
r
a
t
e
s
Analytical interpretation
From the above table all the strength, weaknesses, opportunities and
threats can be analyzed and used in the strategy formulation of the
above five companies of pharmaceutical industry. This information
can also be used in decision making of any important situation.
Finding
The latest org ims rankings of the market shares of pharma companies in the domestic
market for the 12 months ended may have thrown up many insights. in the
cipla10.5%,19.2%,,12.5%,,17.5 %,in the year 2010 -2013
mankind 27.5%, ,
34.5%,,13.5%,,18.5 %,sun farma 15.5%,, 28.5%, 24.1%, ,21.2%, lupin 12.3%,, 18.2%, ,
25.2%,, 12,52% in the year 2010 -2013 ,
The above data the researcher analyze that the CRM policy of mankind company in india
Ensuring executive sponsorship and top management support. Empowering team
members with the required authority to complete the tasks. Selecting the correct
implementation partner. They must have both vertical and horizontal business knowledge,
as well as technical expertise.
From the above table all the strength, weaknesses, opportunities and threats can be
analyzed and used in the strategy formulation of the above five companies of
pharmaceutical industry. This information can also be used in decision making of any
important situation.
Recomdatation
Conclusion
Starting with a turnover of Rs 3.8Cr in 1995 Mankind Pharma is expected to touch Rs 2500 Cr in
2013.
Mankind Pharmaceutical business has been growing at about 18 per cent annually, compared
with the industry average of 13-14 percent. But the profit margin is growing at 12-13%
compared with industry average of 20%.
They operate at profit margin of 13-14% compared to industry average of about 25-30%.
After strategic analysis of five companies namely Lupin, Mankind, GlaxoSmithKline, Pfizer, and
Cipla it can be straight way concluded that their strategies are aligned with their vision and
mission; Lupin heading towards it vision by continuous innovation and healthcare improvement
with having competitive advantage of anti TB drug and cephalosporin, Mankind by its strong
portfolio of businesses, geographies and products range looking forward to achieve its vision,
GlaxoSmithKline investing huge money in R&D and exploring new market to become
indisputable leader of industry, Pfizer by its wide range of medicines and brand image its
fulfilling its promise to deliver innovative product, and Cipla is providing varied range of
medicines to make the customers self-reliant and self-sufficient. These comparative strategic
analyses of these five companies provide the concise analysis of those companies.
Mankind is already present in 90 % of the total market product portfolio. Therefore to launch
new drugs it will need to come up with new dosage forms and delivery systems in much the
way its competitors are doing. Current pricing strategy of Mankind leaves it vulnerable to attacks
from other emerging low price players in the market. Entry of an ultra low cost player can wipe
out Mankind from the market. Another major concern is that there is a perception in the metros
and tier 1 cities that Mankind's drugs are of poor quality simply because they are cheap. For an
aggressive entry in to chronic segment, mankind needs a face change. To substantiate the quality
of their products a modern R&D facility needs to be setup or strategic alliances should be made.
The initial investment is huge and so is promise of high profit margins. It will also enhance
Mankinds image as a legitimate and credible competitor in the global pharmaceutical arena.
Limitation